摘要
目的比较替比夫定和拉米夫定治疗慢性乙型肝炎的效果。方法检索Cochrane library、Pubmed、EMBASE、Web of Science、中国科技期刊(维普)数据库、中国期刊网(CNKI)数据库、万方数据库中替比夫定和拉米夫定治疗慢性乙型肝炎的随机对照研究文献,检索时间截至2013年12月1日。通过Meta分析法比较替比夫定和拉米夫定的疗效。结果共5项随机对照研究符合纳入标准。Meta分析结果显示:替比夫定组的ALT复常率、HBV DNA低于检测下限比例、HBeAg转阴率、HBeAg血清学转换、治疗应答率分别为74.2%、63.7%、36.6%、29.7%、68.6%,拉米夫定组分别为63.7%、42.9%、28.6%、23.8%、52.1%,替比夫定组各指标均优于拉米夫定组,且差异均有统计学意义(均P<0.05)。结论替比夫定比拉米夫定具有更强的抑制乙肝病毒复制的作用,治疗慢性乙型肝炎的效果比拉米夫定更好。
Objective To evaluate the effect of Telbivudine and Lamivudine in the treatment of patients with chronic hepatitis B. Methods Search Cochrane library, Pubmed, EMBASE, Web of Science, China Scientific Journal Database, CNKI database, Wanfang database, literatures of randomized controlled study on Telbivudine and Lamivudine in the treatment of chronic hepatitis B, the search ended in December 1, 2013. Statistical analysis was performed by Metaanalysis to analyze the treatment effect of Telbivudine and Lamivudine. Results 5 randomized controlled trials met the inclusion and exclusion criteria. Meta-analysis showed that patients in Telbivudine group had higher rates of ALT norrealization （74.2%）, lowering of HBV DNA to undetectable levels （63.7%）, loss of HBeAg （36.6%）, HBeAg seroconversion （29.7%）, and therapeutic response （68.6%） as compared with those in Lamivudine group （63.7%, 42.9%, 28.6%, 23.8%, 52.1% respectively）, the differences between the two group were statistically significant （P 〈0.05）. Conclusion Telbivudine shows a better effect than Lamivudine in the treatment of chronic hepatitis B.
出处
《中国医药导报》
CAS
2014年第28期11-13,18,共4页
China Medical Herald
基金
国家科技支撑计划子课题(中国药学会)(编号2013BAI06B04Y023118)
